<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38804985</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>Comparison of the Global Leadership Initiative on Malnutrition and the Patient-Generated Subjective Global Assessment for diagnosing malnutrition in patients undergoing surgery for hepatobiliary and pancreatic malignancies.</ArticleTitle><Pagination><StartPage>835</StartPage><EndPage>842</EndPage><MedlinePgn>835-842</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20960/nh.05056</ELocationID><Abstract><AbstractText>Objective: to analyse the differences in malnutrition assessment between the Global Leadership Initiative on Malnutrition (GLIM) criteria and the Patient-Generated Subjective Global Assessment (PG-SGA) among patients with hepatobiliary and pancreatic malignancies. Method: this study was a cross-sectional study and included 126 hospitalised patients who underwent surgery for hepatobiliary and pancreatic malignancies between November 1, 2019 and August 1, 2020. The patients' clinical data were collected, and malnutrition assessments were completed using the different nutritional assessment tools. The consistency of both tools was analysed using Cohen's kappa coefficient. Results: the prevalence of malnutrition showed a difference in diagnosis results between the GLIM criteria (36.51 %) and the PG-SGA (55.56 %). The two methods had moderate consistency (kappa = 0.590, p &lt; 0.01). The sensitivity of a malnutrition diagnosis using a combination of GLIM and PG-SGA was 65.7 % (53.3 % and 76.4 %, respectively), and specificity was 100 % (92 % and 100 %, respectively). When malnutrition was evaluated using only PG-SGA, sensitivity was 88.9 % (95 % confidence interval (CI) 63.9 % to 98.1 %), whereas when only the GLIM score was used for malnutrition evaluation, sensitivity was 98.2 % (95 % CI, 92.8 % to 99.7 %). In addition, the PG-SGA score and the GLIM score had significant correlations. Conclusion: GLIM performed better than PG-SGA in the correlation analysis of nutritional indicators. GLIM is more suitable for patients with hepatobiliary and pancreatic malignancies than PG-SGA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qin-Hong</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>Department of Nursing. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Hao-Fen</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Outpatient Department. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Hai-Na</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Department of Nursing. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hai-Chao</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery. The First Hospital of Ningbo University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><VernacularTitle>Comparaci&#xf3;n de la Iniciativa Global de Liderazgo sobre la Desnutrici&#xf3;n y la Evaluaci&#xf3;n Global Subjetiva Generada por el Paciente para diagnosticar la desnutrici&#xf3;n en pacientes operados de tumores malignos hepatobiliares y pancre&#xe1;ticos.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044342" MajorTopicYN="Y">Malnutrition</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015596" MajorTopicYN="Y">Nutrition Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="Y">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001661" MajorTopicYN="N">Biliary Tract Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009752" MajorTopicYN="N">Nutritional Status</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Objetivo: analizar las diferencias en la evaluaci&#xf3;n de la desnutrici&#xf3;n en pacientes con tumores malignos hepatobiliares y pancre&#xe1;ticos entre los criterios de la Iniciativa Global de Liderazgo en Desnutrici&#xf3;n (Global Leadership Initiative on Malnutrition, GLIM) y la Evaluaci&#xf3;n Global Subjetiva Generada por el Paciente (PG-SGA). M&#xe9;todos: el estudio fue un estudio transversal que incluy&#xf3; a 126 pacientes hospitalizados que fueron operados de tumores malignos hepatobiliares y pancre&#xe1;ticos entre el 1 de noviembre de 2019 y el 1 de agosto de 2020. Recopilar datos cl&#xed;nicos de pacientes y completar la evaluaci&#xf3;n de la desnutrici&#xf3;n con diferentes herramientas de evaluaci&#xf3;n nutricional. La consistencia de las dos herramientas se analiz&#xf3; utilizando el coeficiente Kappa de Cohen. Resultados: los criterios GLIM (36,51 %) y PG-SGA (55,56 %) presentan diferencias en los resultados diagn&#xf3;sticos de desnutrici&#xf3;n. Ambos m&#xe9;todos tienen una consistencia moderada (kappa = 0590, p &lt; 0,01). La sensibilidad de GLIM y PG-SGA para el diagn&#xf3;stico conjunto de desnutrici&#xf3;n es del 65,7 % (53,3 % y 76,4 %, respectivamente). La especificidad fue del 100 % (92 % y 100 %, respectivamente). Cuando solo se utiliz&#xf3; la PG-SGA para evaluar la desnutrici&#xf3;n, la sensibilidad fue del 88,9 % (intervalo de confianza del 95 % (IC) 63,9 % a 98,1 %), mientras que cuando solo se utiliz&#xf3; la GLIM para evaluar la desnutrici&#xf3;n, la sensibilidad fue del 98,2 % (IC del 95 %: 92,8 % a 99,7 %. Adem&#xe1;s, la puntuaci&#xf3;n PG-SGA tuvo una correlaci&#xf3;n significativa con la puntuaci&#xf3;n GLIM. Conclusi&#xf3;n: en el an&#xe1;lisis de correlaci&#xf3;n de los indicadores nutricionales, GLIM es mejor que PG-SGA. GLIM es m&#xe1;s adecuado para pacientes con tumores malignos hepatobiliares y pancre&#xe1;ticos que PG-SGA.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Evaluaci&#xf3;n nutricional. Tumores malignos hepatobiliares y pancre&#xe1;ticos. Iniciativa Global de Liderazgo sobre la Desnutrici&#xf3;n. Evaluaci&#xf3;n global subjetiva del paciente.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>10</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38804985</ArticleId><ArticleId IdType="doi">10.20960/nh.05056</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38624099</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Ischiorectal Fossa Tumors: 30-year Single-Institution Experience.</ArticleTitle><Pagination><StartPage>896</StartPage><EndPage>902</EndPage><MedlinePgn>896-902</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003255</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Primary tumors of the ischiorectal fossa are rare and comprise a wide array of pathologies with varying malignant potential. Because of the low prevalence, there is a paucity of data in the literature. This article presents a case series on the management of ischiorectal fossa tumors.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present experience from 30 years of managing ischiorectal fossa tumors.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective single-center analysis.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">A quaternary referral academic health care center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients treated for ischiorectal fossa tumors were included in the study.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">All patients underwent surgical management of their disease.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Disease recurrence and overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 34 patients (53% women) were identified with a median follow-up of 23 months. Twenty-one patients (62%) were diagnosed with benign and 13 (38%) with malignant tumors. All underwent surgical resection. The median tumor size was 8.4&#x2009;cm. R0 resection was obtained in 28 patients. Twelve patients (35%) developed recurrence (9 after R0 resection) after a median time of 6.5 months. There were no surgical-related mortalities.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Limitations to the study include its retrospective nature, single-center experience, and small patient sample size.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ischiorectal fossa tumors are primarily benign; however, they are associated with high recurrence rates even in the setting of an R0 resection. Treatment should be approached in a multidisciplinary manner, preferably in centers with experience treating these tumors. Close posttreatment surveillance is imperative. See Video Abstract .</AbstractText><AbstractText Label="TUMORES DE LA FOSA ISQUIORRECTAL EXPERIENCIA DE AOS EN UNA SOLA INSTITUCIN" NlmCategory="UNASSIGNED">ANTECEDENTES:Los tumores primarios de la fosa isquiorrectal son raros y comprenden una amplia gama de patolog&#xed;as con potencial maligno variable. Debido a la baja prevalencia, hay escasez de datos en la literatura. Este art&#xed;culo presenta una serie de casos sobre el tratamiento de los tumores de la fosa isquiorrectal.OBJETIVO:Presentar una experiencia de 30 a&#xf1;os en el manejo de tumores de la fosa isquiorrectal.DISE&#xd1;O:An&#xe1;lisis retrospectivo de un solo centro.AJUSTES:Un centro de atenci&#xf3;n m&#xe9;dica acad&#xe9;mico de referencia cuaternaria.PACIENTES:Todos los pacientes tratados por tumores de la fosa isquiorrectal.INTERVENCIONES:Todos los pacientes se sometieron a tratamiento quir&#xfa;rgico de su enfermedad.PRINCIPALES MEDIDAS DE RESULTADO:Recurrencia de la enfermedad y supervivencia general.RESULTADOS:Se identificaron un total de 34 pacientes (53% mujeres) con una mediana de seguimiento de 23 meses. Veinti&#xfa;n pacientes (62%) fueron diagnosticados con tumores benignos y 13 (38%) con tumores malignos. Todos fueron sometidos a resecci&#xf3;n quir&#xfa;rgica. El tama&#xf1;o medio del tumor fue de 8,4&#x2009;cm. La resecci&#xf3;n R0 se obtuvo en 28 pacientes. Doce (35%) desarrollaron recurrencia (nueve despu&#xe9;s de la resecci&#xf3;n R0) con una mediana de tiempo de 6,5 meses. No hubo mortalidades relacionadas con la cirug&#xed;a.LIMITACIONES:Las limitaciones del estudio incluyen su naturaleza retrospectiva, experiencia en un solo centro y tama&#xf1;o peque&#xf1;o de la muestra de pacientes.CONCLUSIONES:Los tumores de la fosa isquiorrectal son principalmente benignos, sin embargo, se asocian con altas tasas de recurrencia incluso en el contexto de una resecci&#xf3;n R0. El tratamiento debe abordarse de forma multidisciplinaria y preferentemente en centros con experiencia en el tratamiento de estos tumores. Vigilancia cercana posterior al tratamiento es imperativa. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peponis</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0344-899</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>William R G</ForeName><Initials>WRG</Initials></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007512" MajorTopicYN="N">Ischium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>16</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38624099</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003255</ArticleId><ArticleId IdType="pii">00003453-202407000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smyth SL, Dhar S, Cogswell ML, Soleymani Majd H. Ten-step surgical approach to management of pathology of the ischiorectal fossa&#x2014;a review of the literature and application in a rare pelvic schwannoma. J Invest Surg. 2022;35:1067&#x2013;1073.</Citation></Reference><Reference><Citation>Miller M, Kulaylat MN, Ferrario T, Karakousis CP. Resection of tumors of the ischiorectal fossa. J Am Coll Surg. 2003;196:328&#x2013;332.</Citation></Reference><Reference><Citation>Buchs NC, Mortensen NJ, Guy RJ, Gibbons M, George BD. Management of tumors of the ischiorectal fossa: the role of percutaneous biopsy. Dis Colon Rectum. 2015;58:938&#x2013;942.</Citation></Reference><Reference><Citation>Zhu KJ, Lee PJ, Auston KK, et al. Tumors of the ischiorectal fossa: a single-institution experience. Dis Colon Rectum. 2019;62:196&#x2013;202.</Citation></Reference><Reference><Citation>Faria SC, Elsherif SB, Sagebiel T, et al. Ischiorectal fossa: benign and malignant neoplasms of this ignored radiological anatomical space. Abdom Radiol (NY). 2019;44:1644&#x2013;1674.</Citation></Reference><Reference><Citation>Hoeffel C, Crema MD, Azizi L, et al. Magnetic resonance imaging of the ischiorectal fossa: spectrum of disease. J Comput Assist Tomogr. 2007;31:251&#x2013;257.</Citation></Reference><Reference><Citation>Surabhi VR, Garg N, Frumovitz M, Bhosale P, Prasad SR, Meis JM. Aggressive angiomyxomas: a comprehensive imaging review with clinical and histopathologic correlation. AJR Am J Roentgenol. 2014;202:1171&#x2013;1178.</Citation></Reference><Reference><Citation>Steeper TA, Rosai J. Aggressive angiomyxoma of the female pelvis and perineum: report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol. 1983;7:463&#x2013;475.</Citation></Reference><Reference><Citation>Sutton BJ, Laudadio J. Aggressive angiomyxoma. Arch Pathol Lab Med. 2012;136:217&#x2013;221.</Citation></Reference><Reference><Citation>Fine BA, Munoz AK, Litz CE, Gershenson DM. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol. 2001;81:120&#x2013;122.</Citation></Reference><Reference><Citation>McCluggage WG, Jamieson T, Dobbs SP, Grey A. Aggressive angiomyxoma of the vulva: dramatic response to gonadotropin-releasing hormone agonist therapy. Gynecol Oncol. 2006;100:623&#x2013;625.</Citation></Reference><Reference><Citation>Kelley SR, Dozois EJ. Presacral tumors. In: Steele SR, Hull TL, Hyman N, Maykel JA, Read TE, Whitlow CB, eds. The ASCRS Textbook of Colon and Rectal Surgery. 4th ed. Switzerland: Springer Nature; 2022:377&#x2013;378.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37769029</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Clinical and histopathological characteristics of malignant colon tumors by location].</ArticleTitle><Pagination><StartPage>610</StartPage><EndPage>616</EndPage><MedlinePgn>610-616</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.8316446</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The colon has two different embryological origins, which is why it can be divided into right and left with different characteristics each one; therefore, neoplastic lesions have a different clinical picture and are also associated with different pathologies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To describe the clinical and histopathological characteristics of malignant colon tumors acording to their location.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Descriptive, retrospective study with 94 patients diagnosed with colon cancer. Descriptive statistics were performed with the calculation of frequencies and percentages, and chi-squared tests were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Mean age was 61.3 years, 49 (52.1%) were women; 53 (56.4%) were left-sided and 41 (43.6%) right-sided. The main symptom was hematochezia in 32 (60.4%), in patients with left cancer; and diarrhea in 20 (48.8%), in patients with right-sided colon cancer. The presentation of stage I tumors and polyps, p = 0.044 and p = 0.043, respectively, was more frequent on the right side compared to the left side; in the left, hematochezia (p = 0.001), narrow stools(p = 0.05), and a history of type 2 diabetes mellitus (T2DM) (p= 0.036) were more frequent compared to the opposite site.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Stage I and the presence of polyps were more frequent in right-sided cancer compared to left-sided cancer; T2DM, as well as hematochezia and narrow stools were more associated with the left side compared to the right side.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flores-Altamirano</LastName><ForeName>Monserrat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3910-4395</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional "Manuel &#xc1;vila Camacho", Hospital de Especialidades de Puebla, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montiel-Jarqu&#xed;n</LastName><ForeName>&#xc1;lvaro Jos&#xe9;</ForeName><Initials>&#xc1;J</Initials><Identifier Source="ORCID">0000-0003-0531-9611</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional "Manuel &#xc1;vila Camacho", Hospital de Especialidades de Puebla, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Colombo</LastName><ForeName>Aurelio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2855-6161</Identifier><AffiliationInfo><Affiliation>Centro M&#xe9;dico de Especialidades Puebla, Unidad de Diagn&#xf3;stico Gastroenterolog&#xed;a, Servicio de Gastroenterolog&#xed;a. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Bernal</LastName><ForeName>Carlos Alberto</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-3187-0899</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional "Manuel &#xc1;vila Camacho", Hospital de Especialidades de Puebla, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Galicia</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2535-4967</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional "Manuel &#xc1;vila Camacho", Hospital de Especialidades de Puebla, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garza-S&#xe1;nchez</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4919-2934</Identifier><AffiliationInfo><Affiliation>Hospital &#xc1;ngeles Puebla, Servicio Coloproctolog&#xed;a. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas cl&#xed;nicas e histopatol&#xf3;gicas de los tumores malignos de colon por localizaci&#xf3;n.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">el colon tiene dos or&#xed;genes embriol&#xf3;gicos distintos, con lo que se puede dividir en derecho e izquierdo y cada uno tiene caracter&#xed;sticas diferentes; por tanto, las lesiones neopl&#xe1;sicas tienen un cuadro cl&#xed;nico diferente y se asocian tambi&#xe9;n a diferentes patolog&#xed;as.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">describir las caracter&#xed;sticas cl&#xed;nicas e histopatol&#xf3;gicas de los tumores malignos de colon seg&#xfa;n su localizaci&#xf3;n.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio descriptivo, retrospectivo con 94 pacientes con diagn&#xf3;stico de c&#xe1;ncer de colon. La estad&#xed;stica descriptiva se realiz&#xf3; con el c&#xe1;lculo de frecuencias y porcentajes, y se aplicaron pruebas de chi cuadrada.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">la edad media fue 61.3 a&#xf1;os, 49 (52.1%) fueron mujeres; 53 (56.4%) casos fueron izquierdos y 41 (43.6%) derechos. El s&#xed;ntoma principal fue hematoquecia en 32 (60.4%), en pacientes con c&#xe1;ncer izquierdo; y diarrea en 20 (48.8%), en pacientes con c&#xe1;ncer derecho. La presentaci&#xf3;n de tumores en estadio I y p&#xf3;lipos, p = 0.044 y p = 0.043, respectivamente, fue m&#xe1;s frecuente en el lado derecho comparado con el lado izquierdo; en el izquierdo fueron m&#xe1;s frecuentes la hematoquecia (p = 0.001), la disminuci&#xf3;n del grosor de las heces (p = 0.05) y el antecedente de diabetes mellitus 2 (p= 0.036) respecto al sitio contrario.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">el estadio I y la presencia de p&#xf3;lipos fueron m&#xe1;s frecuentes en el c&#xe1;ncer derecho comparado con el izquierdo; la diabetes mellitus 2, as&#xed; como la hematoquecia y la disminuci&#xf3;n en el grosor de las heces se asociaron m&#xe1;s al lado izquierdo en comparaci&#xf3;n con el derecho.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colon, Ascending</Keyword><Keyword MajorTopicYN="N">Colon, Descending</Keyword><Keyword MajorTopicYN="N">Colon, Transverse</Keyword><Keyword MajorTopicYN="N">Colonic Neoplasms</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37769029</ArticleId><ArticleId IdType="pmc">PMC10599786</ArticleId><ArticleId IdType="doi">10.5281/zenodo.8316446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pilleron S, Soto-Perez de Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601&#x2013;8. doi: 10.1002/ijc.33232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33232</ArticleId><ArticleId IdType="pmc">PMC7754149</ArticleId><ArticleId IdType="pubmed">32706917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209&#x2013;49. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran B, Mert Ozupek N, Yerli Tetik N, et al. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Res. 2018;11(4):264&#x2013;73. doi: 10.14740/gr1062w.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/gr1062w</ArticleId><ArticleId IdType="pmc">PMC6089587</ArticleId><ArticleId IdType="pubmed">30116425</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg BA, Marshall JL. Colon Cancer in Young Adults: Trends and Their Implications. Curr Oncol Rep. 2019;21(1):3. doi: 10.1007/s11912-019-0756-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-019-0756-8</ArticleId><ArticleId IdType="pubmed">30659375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SY, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Rev Anticancer Ther. 2018;18(4):351&#x2013;8. doi: 10.1080/14737140.2018.1442217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737140.2018.1442217</ArticleId><ArticleId IdType="pubmed">29458272</ArticleId></ArticleIdList></Reference><Reference><Citation>Imperial R, Ahmed Z, Toor OM, et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Mol Cancer. 2018;17(1):177. doi: 10.1186/s12943-018-0923-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0923-9</ArticleId><ArticleId IdType="pmc">PMC6303985</ArticleId><ArticleId IdType="pubmed">30577807</ArticleId></ArticleIdList></Reference><Reference><Citation>Argil&#xe9;s G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291&#x2013;1305. doi: 10.1016/j.annonc.2020.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.06.022</ArticleId><ArticleId IdType="pubmed">32702383</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukund K, Syulyukina N, Ramamoorthy S, et al. Right and left-sided colon cancers-specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer. 2020;20(1):317. doi: 10.1186/s12885-020-06784-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-06784-7</ArticleId><ArticleId IdType="pmc">PMC7161305</ArticleId><ArticleId IdType="pubmed">32293332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidambi TD, Kohli DR, Samadder NJ, et al. Hereditary Polyposis Syndromes. Curr Treat Options Gastroenterol. 2019;17(4):650&#x2013;665. doi: 10.1007/s11938-019-00251-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11938-019-00251-4</ArticleId><ArticleId IdType="pubmed">31705372</ArticleId></ArticleIdList></Reference><Reference><Citation>Poturnajova M, Furielova T, Balintova S, et al. Molecular features and gene expression signature of metastatic colorectal cancer (Review) Oncol Rep. 2021;45(4) doi: 10.3892/or.2021.7961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2021.7961</ArticleId><ArticleId IdType="pmc">PMC7876998</ArticleId><ArticleId IdType="pubmed">33649827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467&#x2013;1480. doi: 10.1016/S0140-6736(19)32319-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32319-0</ArticleId><ArticleId IdType="pubmed">31631858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidini M, Petrelli F, Tomasello G, et al. Right Versus Left Colon Cancer: Resectable and Metastatic Disease. Curr Treat Options Oncol. 2018;19(6):19&#x2013;31. doi: 10.1007/s11864-018-0544-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-018-0544-y</ArticleId><ArticleId IdType="pubmed">29796712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Villarreal CA, Quiroz-Reyes AG, Islas JF, et al. Colorectal Cancer Stem Cells in the Progression to Liver Metastasis. Front Oncol. 2020;10:1511. doi: 10.3389/fonc.2020.01511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01511</ArticleId><ArticleId IdType="pmc">PMC7468493</ArticleId><ArticleId IdType="pubmed">32974184</ArticleId></ArticleIdList></Reference><Reference><Citation>Char&#xfa;a-Guindic L, Lagunes-Gasca AA, Villanueva-Herrero JA, et al. Comportamiento epidemiol&#xf3;gico del c&#xe1;ncer de colon y recto en el Hospital General de M&#xe9;xico. An&#xe1;lisis de 20 a&#xf1;os: 1988-2007. Rev Gastroenterol Mex. 2009;74(2):99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">19666290</ArticleId></ArticleIdList></Reference><Reference><Citation>Helvaci K, Eraslan E, Yildiz F, et al. Comparison of clinicopathological and survival features of right and left colon cancers. J BUON. 2019;24(5):1845&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">31786846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Cho HJ, Hong JY, et al. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. Ther Adv Med Oncol. 2020;12:1&#x2013;8. doi: 10.1177/1758835920965842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758835920965842</ArticleId><ArticleId IdType="pmc">PMC7649869</ArticleId><ArticleId IdType="pubmed">33224274</ArticleId></ArticleIdList></Reference><Reference><Citation>Vera-Vivas M. C&#xe1;ncer de colon, factores de riesgo y complicaciones en el Hospital de Especialidades Dr. Abel Gilbert Ponton, per&#xed;odo comprendido 2010-2015. Universidad de Guayaquil; [Guayaquil]: 2021. pp. 4&#x2013;16. Tesis de grado.</Citation></Reference><Reference><Citation>Kalantzis I, Nonni A, Pavlakis K, et al. Clinicopathological differences and correlations between right and left colon cancer. World J Clin Cases. 2020;8(8):1424&#x2013;1433. doi: 10.12998/wjcc.v8.i8.1424.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v8.i8.1424</ArticleId><ArticleId IdType="pmc">PMC7190956</ArticleId><ArticleId IdType="pubmed">32368535</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211&#x2013;219. doi: 10.1001/jamaoncol.2016.4227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.4227</ArticleId><ArticleId IdType="pubmed">27787550</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltr&#xe1;n L, Gonz&#xe1;lez-Trejo S, Carmona-Herrera DD, et al. Prognostic factors and differences in survival of right and left colon carcinoma: a STROBE compliant retrospective cohort study. Arch Med Res. 2019;50(2):63&#x2013;70. doi: 10.1016/j.arcmed.2019.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2019.05.011</ArticleId><ArticleId IdType="pubmed">31349955</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Duanmu J, Liu Y, et al. Analysis of multi-omics differences in left-side and right-side colon cancer. PeerJ. 2021;9:1&#x2013;23. doi: 10.7717/peerj.11433.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.11433</ArticleId><ArticleId IdType="pmc">PMC8123232</ArticleId><ArticleId IdType="pubmed">34026368</ArticleId></ArticleIdList></Reference><Reference><Citation>Quezada-Guti&#xe9;rrez C, &#xc1;lvarez-Ba&#xf1;uelos MT, Morales-Romero J, et al. Factors associated with the survival of colorectal cancer in Mexico. Intest Res. 2020;18(3):315&#x2013;324. doi: 10.5217/ir.2019.09179.</Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2019.09179</ArticleId><ArticleId IdType="pmc">PMC7385577</ArticleId><ArticleId IdType="pubmed">32418415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Cancer Netw. 2017 Mar;15(3):411&#x2013;419. doi: 10.6004/jnccn.2017.0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2017.0038</ArticleId><ArticleId IdType="pubmed">28275039</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles A, Bashashati M, Contreras A, et al. Colorectal Cancer in Hispanics Living Near the U.S.-Mexico Border. Rev Invest Clin. 2019;71(5):306&#x2013;310. doi: 10.24875/RIC.19003026.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/RIC.19003026</ArticleId><ArticleId IdType="pubmed">31599880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37084299</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>MSH-5: malignant knee tumors timely detection index.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>152</EndPage><MedlinePgn>146-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.21000907</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bone neoplasms are usually misdiagnosed causing a delay in their treatment. Bone neoplasms are usually confused with tendinitis, 31% of the cases corresponds to osteosarcomas and in 21% to Ewing's sarcomas.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To create a clinical-radiographic instrument of high diagnostic suspicion of knee bone neoplasms to prevent a delay in diagnosis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A clinimetric study (sensitivity, consistency and validity) was performed in the bone tumor service, Hospital de Ortopedia de la Unidad M&#xe9;dica de Alta Especialidad Dr. Victorio de la Fuente Narv&#xe1;ez, Instituto Mexicano del Seguro Social, in M&#xe9;xico City.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Characteristics of 153 patients were collected. For the sensitivity phase, 3 domains (signs, symptoms, and radiology) and 12 items were included. Consistency was evaluated with ICC (0.944), 95%CI (0.865-0.977), p &lt; 0.001 and a-Cronbach (0.863). Index obtained a sensitivity of 0.80 and a specificity of 0.882 were obtained. The positive predictive value of the test was 66.6% and the negative predictive value was 93.75%. The positive likelihood ratio was 6.8 and the negative likelihood ratio was 0.2. Validity was evaluated using r-Pearson (0.894; p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A high suspicion clinical-radiographic index was designed to detect malignant knee tumors with adequate sensitivity, specificity, appearance, content, criteria, and construct validity.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivera-Sald&#xed;var</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Gonz&#xe1;lez</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Coordinaci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Unidad M&#xe9;dica de Alta Especialidad Dr. Victorio de la Fuente Narv&#xe1;ez, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cario-M&#xe9;ndez</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe9;cualt-G&#xf3;mez</LastName><ForeName>Romeo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaya-Zepeda</LastName><ForeName>Rub&#xe9;n A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alc&#xe1;ntara-Corona</LastName><ForeName>Armando</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes-Figueroa</LastName><ForeName>Silvestre</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Tumores &#xd3;seos.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>MSH-5: &#xed;ndice para la detecci&#xf3;n oportuna de tumores malignos de rodilla.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="Y">Bone Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007717" MajorTopicYN="Y">Knee</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">Los tumores &#xf3;seos suelen ser subdiagnosticados, provocando un retraso en su tratamiento. El diagn&#xf3;stico err&#xf3;neo m&#xe1;s frecuente es tendinitis, en el cual el 31% corresponden a osteosarcomas y el 21% a sarcomas de Ewing.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Crear un instrumento cl&#xed;nico-radiogr&#xe1;fico de alta sospecha diagn&#xf3;stica de tumores &#xf3;seos de rodilla.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Se realiz&#xf3; un estudio clinim&#xe9;trico (sensibilidad, consistencia y validez) en el servicio de tumores &#xf3;seos del Hospital de Ortopedia de la Unidad M&#xe9;dica de Alta Especialidad Dr. Victorio de la Fuente Narv&#xe1;ez, Instituto Mexicano del Seguro Social, en Ciudad de M&#xe9;xico.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">El &#xed;ndice se realiz&#xf3; tomando las caracter&#xed;sticas de 153 pacientes. Para la fase de sensibilidad se incluyeron tres dominios (signos, s&#xed;ntomas y radiolog&#xed;a) y 12 &#xed;tems. La consistencia se evalu&#xf3; con coeficiente de correlaci&#xf3;n intraclase (0.944), intervalo de confianza del 95% (0.865-0.977), p &lt; 0.001 y &#x3b1; de Cronbach (0.863). Se obtuvo una sensibilidad del instrumento de 0.80 y una especificidad de 0.882. El valor predictivo positivo de la prueba fue del 66.6% y el valor predictivo negativo fue de 93.75%. La raz&#xf3;n de verosimilitud positiva fue de 6.8 y la raz&#xf3;n de verosimilitud negativa fue de 0.2. La validez se evalu&#xf3; mediante r-Pearson (0.894; p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Se dise&#xf1;&#xf3; un &#xed;ndice cl&#xed;nico-radiogr&#xe1;fico de alta sospecha para detectar tumores malignos de rodilla con adecuada sensibilidad, especificidad y validez de apariencia, de contenido, de criterio y de constructo.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone neoplasms</Keyword><Keyword MajorTopicYN="N">Diagn&#xf3;stico temprano</Keyword><Keyword MajorTopicYN="N">Dolor</Keyword><Keyword MajorTopicYN="N">Early diagnosis</Keyword><Keyword MajorTopicYN="N">Exploraci&#xf3;n f&#xed;sica</Keyword><Keyword MajorTopicYN="N">Knee</Keyword><Keyword MajorTopicYN="N">Pain</Keyword><Keyword MajorTopicYN="N">Physical Examination</Keyword><Keyword MajorTopicYN="N">Radiograf&#xed;a</Keyword><Keyword MajorTopicYN="N">Radiography</Keyword><Keyword MajorTopicYN="N">Rodilla</Keyword><Keyword MajorTopicYN="N">Tumores &#xf3;seos</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>15</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37084299</ArticleId><ArticleId IdType="doi">10.24875/CIRU.21000907</ArticleId><ArticleId IdType="pii">j91/2/146</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36858783</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2173-5735</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Acta otorrinolaringologica espanola</Title><ISOAbbreviation>Acta Otorrinolaringol Esp (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Sinonasal adenocarcinomas: Retrospective analysis from an oncology center.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>22</EndPage><MedlinePgn>15-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.otoeng.2021.10.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5735(23)00017-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">Sinonasal adenocarcinomas are rare and heterogeneous tumors and for this reason remain understudied. Our purpose is to analyze clinical presentation, outcomes and factors affecting survival of patients with sinonasal adenocarcinomas, treated at our institution.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Retrospective review of clinical records of patients with sinonasal adenocarcinoma, treated at a tertiary oncology institution (January 2010 to December 2019).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty patients diagnosed with adenocarcinoma were included, with male preponderance (54.90%) and a mean age of 57.5&#xb1;14.9 years. Adenocarcinoma was the most frequent type of sinonasal cancer, contrary to previous reports from our institution. In most patients, it was detected at an advanced disease stage, significantly decreasing their survival rate when compared to patients diagnosed at initial stages (p&lt;0.029). Intestinal type adenocarcinoma was established in 47 patients, the most frequent being the colonic subtype (24%). Tumors with good/moderate histologic differentiation presented a survival advantage over those that were poorly differentiated (p=0.043). The most common treatment modality was surgery followed by radiotherapy. Endoscopic resection was performed in 53% of the patients and an external approach was used in 40% of the patients. Estimated overall survival rates at 3 and 5-years were 64% and 53%, respectively, and cancer specific survival 72% and 65%, for the same period. Recurrence rate was 32% and occurred mainly locally. Disease Free Survival rate was 71% at 3 years and 65% at 5 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite being the most common sinonasal malignancy in our sample, in contrast to other series, sinonasal adenocarcinomas are still rare tumors with a substantial local failure rate of around 30%. Advanced stage at diagnosis and histologic differentiation grade negatively affected prognosis of these tumors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Otorrinolaringolog&#xed;a y Cirug&#xed;a de Cabeza y Cuello. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lombo</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology of Instituto Portugu&#xea;s de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal; Department of Otorhinolaryngology of Hospital Senhora da Oliveira de Guimar&#xe3;es, Braga, Portugal. Electronic address: catarina.rlombo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro Silva</LastName><ForeName>Joaquim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology of Instituto Portugu&#xea;s de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteiro</LastName><ForeName>Eurico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology of Instituto Portugu&#xea;s de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Acta Otorrinolaringol Esp (Engl Ed)</MedlineTA><NlmUniqueID>101770938</NlmUniqueID><ISSNLinking>2173-5735</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010255" MajorTopicYN="Y">Paranasal Sinus Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adenocarcinoma</Keyword><Keyword MajorTopicYN="N">Adenocarcinoma histology</Keyword><Keyword MajorTopicYN="N">Adenocarcinoma survival</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer nasal</Keyword><Keyword MajorTopicYN="N">Histolog&#xed;a del adenocarcinoma</Keyword><Keyword MajorTopicYN="N">Nasal cancer</Keyword><Keyword MajorTopicYN="N">Sinonasal malignancies</Keyword><Keyword MajorTopicYN="N">Supervivencia del adenocarcinoma</Keyword><Keyword MajorTopicYN="N">Tumores malignos sinonasales</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36858783</ArticleId><ArticleId IdType="doi">10.1016/j.otoeng.2021.10.005</ArticleId><ArticleId IdType="pii">S2173-5735(23)00017-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36623890</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2529-8496</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Neurocirugia</Title><ISOAbbreviation>Neurocirugia (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Microsurgical free flaps for skull base reconstruction following tumor resection: Available techniques and complications.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>31</EndPage><MedlinePgn>22-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neucie.2022.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2529-8496(22)00075-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Resection of malignant tumors located in the anterior and middle fossae of the skull base requires thorough anatomical knowledge, as well as experience regarding the possible reconstructive options to resolve the resulting defects. The anatomical and functional relevance of the region, the complexity of the defects requiring reconstruction and the potential complications that can occur, represent a true challenge for the surgical team. The goal of this study is to describe the microsurgical reconstructive techniques available, their usefulness and postoperative complications, in patients with malignant tumors involving the skull base.</AbstractText><AbstractText Label="MATERIALS AND METHOD">This observational, retrospective study, included all patients who underwent surgery for malignant craniofacial tumors from January 1st, 2009 to January 1st, 2019 at a University Hospital in Argentina. Only patients who required reconstruction of the resulting defect with a free flap were included.</AbstractText><AbstractText Label="RESULTS">Twenty-four patients required reconstruction with FF; 14 were male (58.3%) and mean age was 54.9 years. Sarcoma was the most frequent tumor histology. Free flaps used were the following: anterolateral thigh, rectus abdominis, radial, latissimus dorsi, iliac crest and fibular. Complications occurred in 6 cases and no deaths were reported in the study group.</AbstractText><AbstractText Label="CONCLUSION">Free flaps are considered one of the preferable choices of treatment for large skull base defects. In spite of the complexity of the technique and the learning curve required, free flaps have shown to be safe, with a low rate of serious complications. For these patients, the surgical resolution should be performed by a multidisciplinary team.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Neurocirug&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plou</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Hospital Italiano de Buenos Aires, Argentina. Electronic address: pedro.plou@hospitalitaliano.org.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccalatte</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Head and Neck Surgery, Department of General Surgery, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla-Lichtenberger</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figari</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Head and Neck Surgery, Department of General Surgery, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajler</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larra&#xf1;aga</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Head and Neck Surgery, Department of General Surgery, Hospital Italiano de Buenos Aires, Argentina; Section of Reconstructive Surgery, Department of General Surgery, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurocirugia (Engl Ed)</MedlineTA><NlmUniqueID>101778588</NlmUniqueID><ISSNLinking>2529-8496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058752" MajorTopicYN="Y">Free Tissue Flaps</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="Y">Plastic Surgery Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019291" MajorTopicYN="N">Skull Base</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cirug&#xed;a de la base del cr&#xe1;neo</Keyword><Keyword MajorTopicYN="N">Colgajo libre</Keyword><Keyword MajorTopicYN="N">Free flap</Keyword><Keyword MajorTopicYN="N">Malignant tumors</Keyword><Keyword MajorTopicYN="N">Reconstrucci&#xf3;n de la base del cr&#xe1;neo</Keyword><Keyword MajorTopicYN="N">Skull base reconstruction</Keyword><Keyword MajorTopicYN="N">Skull base surgery</Keyword><Keyword MajorTopicYN="N">Tumores malignos</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36623890</ArticleId><ArticleId IdType="doi">10.1016/j.neucie.2022.11.005</ArticleId><ArticleId IdType="pii">S2529-8496(22)00075-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>